
Mainz, Germany | full time | Job ID: 11389
About the Role:
As the Product Owner for Vulnerability Management & Effectiveness, you will oversee our IT vulnerability management program, ensuring effective identification, assessment, and tracking of vulnerabilities. In this strategic advisory role, you will define processes, set up scans, create incidents based on findings, and coordinate remediation efforts with responsible teams. Additionally, you will plan penetration testing and red teaming activities while maintaining the vulnerability management solution. Your focus will be on process management and stakeholder coordination rather than hands-on technical implementation.
Your Contribution:
A Good Match:
Your Benefits:
It's our priority to support you:
Apply now - We look forward to your application!
Apply to our Mainz, Germanylocation by sending us your documents via our online form. For any questions, contact our talent acquisition team on: + 49 (0) 6131-9084-1291 (Monday-Friday from 1 PM to 3 PM CET).
Job ID 11389 (please always specify if you have any questions)
By submitting your application, you acknowledge that a background check will be conducted as part of the recruitment process in accordance with applicable laws and regulations. If you are considered for the position, BioNTech will conduct the background check through our service provider ‘HireRight’. You will be informed accordingly by your BioNTech-Recruiter.

Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases.
BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress.
BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years.
Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: https://www.biontech.com/int/en/home/careers.html
🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html
🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html